Corbus Pharmaceuticals Holdings, Inc. CRBP
7.14
(0.31)
(4.16%)
as of 25 Sep
- Market cap
- $144.1M
- P/E
- 0.0×
Follow CRBP
Insider Buys
alert about insiders buying in the last 12 month
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/S ratio |
181.67 | 163.31 | 68.96 | 9.64 | 24.78 | 49.14 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/Operating CF |
(63.39) | (43.73) | (23.64) | (15.45) | (5.35) | (7.80) | — | — | — | — |
P/B ratio |
38.94 | 6.90 | 12.08 | 56.60 | 2.16 | 1.10 | — | — | — | — |
Price to Tangible BV |
38.94 | 6.90 | 12.08 | 56.60 | 2.16 | 1.10 | — | — | — | — |
EV/Sales |
174.01 | 137.84 | 60.43 | 9.01 | 7.75 | (1.73) | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | — | — | — | — |
EV/Operating CF |
(24.51) | (12.10) | (9.69) | (7.12) | (0.31) | 0.06 | — | — | — | — |
EV/FCF |
(23.89) | (11.80) | (9.00) | (6.72) | (0.30) | 0.06 | — | — | — | — |
Quick Ratio |
1.85 | 7.64 | 2.31 | 0.99 | 2.72 | 5.75 | 4.70 | 0.66 | 12.64 | 7.92 |
Current Ratio |
1.96 | 7.98 | 2.45 | 1.09 | 2.89 | 5.89 | 4.76 | 0.74 | 12.94 | 8.07 |
Net Debt/EBITDA |
0.75 | 1.93 | 0.74 | 0.30 | 0.55 | 1.48 | 1.05 | 0.11 | 2.92 | 1.90 |
Debt/Assets |
1.55% | 0.50% | 0.84% | 18.01% | 18.32% | 18.10% | 28.85% | 57.33% | 0.00% | 0.00% |
Debt/Equity |
0.03 | 0.01 | 0.01 | 1.44 | 0.41 | 0.28 | 0.58 | (2.35) | 0.00 | 0.00 |
Asset Turnover |
0.12 | 0.06 | 0.08 | 0.75 | 0.05 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.68 | 0.86 | 0.54 | 0.64 | 0.90 | 1.06 | 0.89 | 0.81 | 1.04 | 0.82 |
Capex/Depreciation |
(4.03) | (2.77) | (4.66) | (2.23) | (0.24) | (0.01) | 0.00 | 0.00 | 0.00 | 0.01 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (223.40%) | (97.21%) | (130.52%) | (424.29%) | (432.68%) | (79.80%) | (82.95%) | (341.99%) | (59.34%) | (54.18%) | |
| (130.02%) | (76.41%) | (97.70%) | (148.66%) | (146.95%) | (43.46%) | (48.66%) | (94.32%) | (43.67%) | (48.47%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(223.71%) | (55.20%) | (192.93%) | (855.64%) | (173.20%) | (53.32%) | (86.15%) | 604.80% | (28.41%) | (53.64%) |
Average Days of Receivables |
254.05 | 0.00 | 0.00 | 27.08 | 89.00 | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
807.61% | 1,067.08% | 1,008.11% | 247.91% | 2,495.87% | 4,133.53% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
337.96% | 367.35% | 268.67% | 65.42% | 723.36% | 2,316.59% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
165.51% | 233.36% | 157.80% | 33.15% | 316.42% | 1,103.60% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.02 | 0.14 | 0.07 | (0.01) | 0.36 | 0.81 | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(5.80%) | (8.18%) | (16.80%) | (20.72%) | (118.52%) | (63.38%) | — | — | — | — |
Free Cash Flow Yield |
(4.01%) | (7.15%) | (9.73%) | (13.90%) | (102.67%) | (63.71%) | — | — | — | — |
Revenue per Share |
1.40 | 1.46 | 2.54 | 16.99 | 1.51 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(9.91) | (16.64) | (15.84) | (21.49) | (38.31) | (11.77) | (9.00) | (8.34) | (3.83) | (4.84) |
Capex per Share |
(0.26) | (0.42) | (1.21) | (1.29) | (0.19) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(10.16) | (17.06) | (17.05) | (22.78) | (38.50) | (11.77) | (9.00) | (8.34) | (3.83) | (4.84) |
Cash per Share |
11.05 | 37.52 | 21.99 | 14.92 | 32.97 | 23.89 | 14.24 | 4.88 | 13.68 | 12.31 |
Shareholders Equity per Share |
6.51 | 34.58 | 14.50 | 2.89 | 17.40 | 16.88 | 7.91 | (1.60) | 13.05 | 11.08 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.51 | 34.58 | 14.50 | 2.89 | 17.40 | 16.88 | 7.91 | (1.60) | 13.05 | 11.08 |
Free Cash Flow |
(13.92) | (28.50) | (32.37) | (48.46) | (100.17) | (48.21) | (37.55) | (36.10) | (41.79) | (64.50) |
Working Capital |
8.50 | 57.30 | 26.15 | 3.27 | 60.18 | 83.20 | 47.54 | (8.35) | 141.16 | 146.26 |
Capital Expenditures |
(0.35) | (0.71) | (2.30) | (2.74) | (0.48) | (0.03) | (0.01) | — | — | (0.01) |
Net Current Asset Value |
8.43 | 56.31 | 24.78 | (4.83) | 35.05 | 61.58 | 26.86 | (11.63) | 139.53 | 146.26 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | — | — | — | — |
Capex to Sales |
0.18 | 0.29 | 0.48 | 0.08 | 0.12 | 0.03 | 0.00 | — | — | 0.00 |
Net Profit Margin |
(1,046.29%) | (1,328.65%) | (1,154.47%) | (197.69%) | (2,826.10%) | (5,176.41%) | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.20 | 0.18 | 0.18 | 0.24 | 0.49 | 1.27 | 1.01 | 0.99 | (6.09) | (7.13) |
Cash ROIC |
(57.55%) | (24.19%) | (47.04%) | (108.66%) | (69.26%) | (27.13%) | (35.12%) | (121.94%) | (14.46%) | (20.76%) |
Accounts Receivable Turnover |
0.95 | 0.00 | 0.00 | 18.02 | 2.16 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
2.01 | — | — | 2.01 | 1.82 | — | — | — | — | — |
Average Payables |
2.37 | 3.28 | 4.74 | 8.72 | 9.24 | 4.58 | 1.98 | 2.68 | 3.98 | 3.50 |
Average Assets |
15.38 | 42.43 | 56.98 | 48.07 | 75.72 | 105.01 | 87.02 | 47.29 | 92.08 | 162.04 |
Average Common Equity |
8.95 | 33.35 | 42.65 | 16.84 | 25.72 | 57.19 | 51.05 | 13.04 | 67.76 | 144.97 |
Columns are period end dates